Cubist gets option to acquire pain management biotech Adynxx; option not exercised
- Antisense, Oligonucleotides
- Large Molecule
- Intra-Biotech Deal
- Includes Earnout
- Full Acquisition
- Payment Includes Cash
- Acquisition of Private Biotech
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.